Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium


Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented Excerpt from the Press Release: PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for…

Read More

Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021


ATA2271 targets difficult-to-treat solid tumors using proprietary 1XX CAR signaling and intrinsic PD-1 checkpoint inhibition technology Ongoing Phase 1 dose-escalation trial in advanced mesothelioma shows promising early safety and persistence of armored CAR T cells in patients Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy,…

Read More

Strategy to overcome tumors’ resistance to immunotherapy generates promising clinical trial results


Responses to immune checkpoint inhibitors improved after adding radiation therapy. Date:November 18, 2021 Source:Massachusetts General Hospital Summary:Immune checkpoint inhibitors strengthen the immune response against cancer cells, but the medications are ineffective against certain tumors. Results from a new clinical trial indicate that adding radiation may overcome this resistance to immune checkpoint inhibitors. Excerpt from the…

Read More